Stryker Corporation

Stryker Corporation

SYKNYSE / NASDAQHealthcareLarge cap

$310.00-$3.08 (-1.0%)

Last close · Data as of Nov 20, 2026

Market cap
$115.5B
P/E
35.6x
EV / EBITDA
20.2x
Revenue
$25.1B
Net margin
12.9%
ROCE
12.6%

-14.0% over the last year

Stryker Corporation price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+1.8%
3M
-5.4%
6M
-3.6%
1Y
-14.0%
5Y
+17.6%

52-week range

Day change -$3.08 (-1.0%) from $313 to $310 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in SYK, bought on each weekday since 2021.

News & filings

What Stryker filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthOperating margin of 20.1% against a peer median of 19.3%.

Concerns (1)

  • The P/E of 35.6 is 71% above the peer median of 20.8.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics.

Read moreShow less

Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.

Sector
Healthcare
Shares outstanding
382.3M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$115.5B
P/E
35.6x
P/B
5.2x
EV / EBITDA
20.2x
EV / Sales
5.1x
P/S
4.6x
52-week high
$387.46
52-week low
$269.75

Profitability

Operating margin
20.1%
Net margin
12.9%
EBITDA margin
25.1%
ROE
14.5%
ROCE
12.6%
ROA
6.8%
Asset turnover
0.52

Growth

Revenue
$25.1B
Revenue growth, 1Y
11.2%
Revenue CAGR, 3Y
10.8%
Net profit growth, 1Y
8.5%
Free cash flow
$4.3B

Solvency

Current ratio
1.89
Debt / Equity
0.71
Debt / Assets
0.33
CFO / Net profit
1.55
Cash / Market cap
3.5%

Where the revenue went

Of every $100 of FY2025 revenue, $13 was left as net income.

Stryker Corporation income statement flow, FY2025
Stryker Corporation income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$9.1B
RevenueGross profit$16.1B
Gross profitResearch and development$1.6B
Gross profitSelling, general and administrative$8.7B
Gross profitOther operating expenses$732.0M
Gross profitOperating income$5.1B
Operating incomePretax income$4.5B
Operating incomeInterest and other expense$545.0M
Pretax incomeTax and other$1.3B
Pretax incomeNet income$3.2B

Revenue and net profit

Revenue grew 11.2% in FY2025; net profit is the dashed line.

Stryker Corporation revenue and net profit by fiscal year
Stryker Corporation revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$18.4B$2.4B
FY2023$20.5B$3.2B
FY2024$22.6B$3.0B
FY2025$25.1B$3.2B

Cash flows

FY2025: $5.0B from operations, $4.3B free after investment (dashed).

Stryker Corporation operating and free cash flow by fiscal year
Stryker Corporation operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$2.6B$2.0B
FY2023$3.7B$3.1B
FY2024$4.2B$3.5B
FY2025$5.0B$4.3B

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$25.1B+11.2%1Y
EBITDA
$6.3B+27.5%1Y
Net profit
$3.2B+8.5%1Y
Cash from operations
$5.0B+18.9%1Y
Free cash flow
$4.3B+22.8%1Y
Revenue CAGR, 3Y
10.8%
Net profit CAGR, 3Y
11.2%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$25.1B$6.3B$3.2B$4.3B14.5%+11.2%+8.5%

Monthly returns

Month-by-month returns of SYK across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$47.8B
Liabilities$25.4B
Equity$22.4B
Paid-in capital$2.6B
Retained earnings$20.5B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; SYK highlighted.

P/E against peers

SYK trades at 35.6x earnings against a peer median of 20.8x (a 71% premium).

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Stryker CorporationSYKthis companyP/E ↑ premium$115.5B35.6x5.2x14.5%20.2x
Pfizer Inc.PFE$146.4B18.8x1.7x9.0%12.5x
Danaher CorporationDHR$132.1B36.6x2.5x6.9%21.2x
CVS Health CorporationCVS$121.0B68.4x1.6x2.4%19.5x
Bristol-Myers Squibb CompanyBMY$115.6B16.4x6.3x38.2%10.0x
Vertex Pharmaceuticals IncorporatedVRTX$112.1B28.4x6.0x21.2%22.4x
Medtronic plcMDT$105.2B22.6x2.2x9.7%14.3x
McKesson CorporationMCK$91.0B19.1x-41.9x-219.2%13.3x
Elevance Health, Inc.ELV$88.9B15.7x2.0x12.9%—
Peer median—20.8x2.1x9.3%14.3x

Year-to-date ROI

SYK since 1 January, against earlier years.

Historical volatility

SYK's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Stryker Corporation operating margin by fiscal year
Stryker Corporation operating margin by fiscal year
DateOperating margin
FY202216.9%
FY202319.1%
FY202420.7%
FY202520.1%
LineFY2025
Cost of revenueCost Of Revenue$9.1B
Gross profitGross Profit$16.1B
Operating expensesOperating Expense$11.0B
Research and developmentResearch And Development$1.6B
Selling, general and administrativeSelling General And Administration$8.7B
Depreciation and amortisationDepreciation And Amortization In Income Statement$732.0M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$732.0M
Amortization$732.0M
Amortisation of intangiblesAmortization Of Intangibles Income Statement$732.0M
Total expensesTotal Expenses$20.1B
Pretax incomePretax Income$4.5B

Learn while you research

Academy chapters picked for Stryker Corporation and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Valuation Multiples ExplainedThis stock trades at a P/E of 35.6, learn when high multiples are justified.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →